CD155-CD96 keeps quiescent persister tumor cells in check.

In this issue of Developmental Cell, Geng et al. show that quiescent persister tumor cells (PTCs) in colorectal cancer are enriched after neoadjuvant chemotherapy and exhibit increased expression of CD155, leading to dysfunction of tumor-infiltrating CD96+CD8+ T cells. Anti-tumor activity can be restored through CD96-targeted monoclonal antibody therapy.